Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States

INTRODUCTION: Data from the SINGLE trial demonstrated that 88% of treatment-naive HIV-1 patients treated with dolutegravir and abacavir/lamivudine (DTG+ABC/3TC) achieved viral suppression at 48 weeks compared with 81% of patients treated with efavirenz/tenofovir disoproxil fumarate/emtricitabine (EF...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Int AIDS Soc
Hoofdauteurs: Peng, Siyang, Tafazzoli, Ali, Dorman, Emily, Rosenblatt, Lisa, Villasis-Keever, Angelina, Sorensen, Sonja
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: International AIDS Society 2014
Onderwerpen:
Poster Sessions – Abstract P073
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4224816/
https://ncbi.nlm.nih.gov/pubmed/25394109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19605
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items